Organ-specific autoimmunity: a 1986 overview
- PMID: 3026954
- PMCID: PMC7165626
- DOI: 10.1111/j.1600-065x.1986.tb01168.x
Organ-specific autoimmunity: a 1986 overview
Abstract
The normally functioning immune system is subject to intricate networks of regulatory mechanisms: it is therefore not surprising to find that autoimmune diseases present a complex pathogenic picture in which the relative contributions of various factors probably determine the precise nature and course of disease. This is particularly evident in the effector mechanisms of organ-specific autoimmunity which are described in this chapter. These ultimately give rise to the disease symptoms, and can be directly cytotoxic, or may either stimulate or block functional activity or growth of the target cells. Their various contributions to human diseases are becoming more firmly established, as in Type I diabetes, or are only now being described, as in the case of EC-Ab in protracted diarrhea of infancy and as evidenced by the growing lists of receptor-stimulating or -blocking antibodies. The nature and precise location of relevant autoantigens is also coming under closer scrutiny. The answers to the question of why these diseases arise in the first place remain more elusive. However, it is again likely that a variety of factors can contribute. The attractive possibility of a role for idiotypic interactions is gaining ground, particularly within the context of antibodies to hormones and their receptors. Another potential mechanism which we believe may be of central importance, particularly in the development of organ-specific destructive autoimmunity, and which we have discussed here in detail, is the aberrant expression of HLA Class II molecules by target cells. Whether this is actually an initiating factor is presently not known, but its potential for promoting pathogenesis both early and late in the process is clear. Furthermore, the complex nature of the regulation of epithelial Class II expression may help to explain the heterogeneity of features and course of disease in different patients with the same underlying pathology. All these advances in our basic understanding of the disease processes should ultimately lead to more effective and specific means of therapeutic intervention.
References
-
- Adams, D. D. , (1956) The clinical status of patients whose sera have given the abnormal response when assayed for thyrotropin. Proc. Univ. Otago. Med. Sch. 34, 29–35.
-
- Adams, D. D. (1958) The presence of an abnormal thyroid‐stimulating hormone in the serum of some thyrotoxic patients. J. Clin. Endocrinol. Metab. 18, 699–712. - PubMed
-
- Aichinger, G. , Fill, H. & Wick, G. (1985) In situ immune complexes, lymphocytes subpopulations and HLA‐DR positive epithelial cells in Hashimoto thyroiditis. Lab. Invest. 52, 132–140. - PubMed
-
- Alviggi, L. , Johnston, C. , Hoskins, P. J. , Tee, D. E. H. , Pyke, D. A. , Leslie, R. G. D. & Vergani, D. (1984) Pathogenesis of insulin dependent diabetes: A role for activated T‐ lymphocytes. Lancet ii, 4–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
